Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study

Ítems similars

• Maintenance of efficacy of canakinumab in SJIA at the individual patient level in a 12-week pooled dataset
  per: Ravelli, A, et al.
  Publicat: (2014)
• Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA – an analysis of 12-week pooled data
  per: Ravelli, A, et al.
  Publicat: (2014)
• Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
  per: Wulffraat, NM, et al.
  Publicat: (2014)
• PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients
  per: Quartier, P, et al.
  Publicat: (2013)
• Efficacy of canakinumab in biologic-naïve versus previously biologic-exposed SJIA patients: a 12 week pooled post-hoc analysis
  per: Quartier, P, et al.
  Publicat: (2014)